Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) Yahoo Finance Nawigacja wpisu Ending the disabling pain of carpal tunnel syndrome – 6abc Philadelphia Editas Medicine Announces First Quarter 2025 Results and Business Updates – Yahoo Finance
